DRUG SHOWS NEW PROMISE FOR BREAST CANCER TREATMENT
Professor Wayne Tilley from the University of Adelaide has contributed critical research findings that led to the new clinical trial which tests Enobosarm and other AR modulator drugs as treatment options for women with ER-positive breast cancer.
Treatments for hormone-related breast cancers are often associated with debilitating side effects, leaving patients feeling miserable. Professor Tilley emphasised the importance of patient well-being whilst being treated for breast cancer.
“We have been advocates for Enobosarm and similar drugs because they not only have the potential to prolong life, but they have the potential to make patients feel better while on therapy,” he explained. “This reduction in negative side effects is because the drugs promote bone, muscle and brain health.”
Read more on Professor Wayne Tilley’s work here.
“Funding for this pilot study by the NBCF has provided evidence to justify continuing this avenue of research and to translate it into clinical practice. Thank you for supporting our efforts to provide effective and very tolerable means to treat this awful disease.” Professor Wayne Tilley, NBCF-funded researcher
WHY THIS PROJECT IS SO IMPORTANT FOR WOMEN LIKE LUCIJA
“Every little piece of Dr Wayne Tilley’s research into reducing side effects adds to a river stream of hope for people affected by breast cancer.” Lucija, diagnosed 2013.
MORE ABOUT LUCIJA
Lucija was diagnosed with ER Positive breast cancer in 2013, just days after Christmas. She had a host of treatments, including a lumpectomy, hormone therapy, chemotherapy and radiotherapy.
Lucija remains passionate about highlighting the importance of research for future generations impacted by the disease.
“The incredible advances we have seen in treatment due to research gives each of us a feeling of hope that zero deaths from breast is just around the corner,” she says.